I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs.
Elizabeth Mutisya
Vice President, US Medical Affairs, Chief Medical Officer, Solvay Pharmaceuticals
I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs. I am proud that I have been able to focus the companies I've been part of on the hidden value in existing or prospective assets—a creative approach to planning for the future. At each juncture, I have been open to the full range of possibilities, and have taken the time to think about which of several paths made the most sense given my personal mission to have a tangible, positive impact on patients, my community, and the health of society at large.
Ultimately, we need to do a better job of delineating the value that our industry provides in addressing medical problems. Health economics and outcomes research is one way we can accomplish this. It allows us to better quantify the benefits of our solutions to patient outcomes, health-related quality of life, and individuals involved in patient care. It also enables us to think more holistically about the impact of a particular intervention or preventive measure on overall healthcare costs. At Solvay, I have focused on this and other ways we can prepare for the healthcare environment of tomorrow.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.